** Shares of healthcare AI firm Tempus AI TEM.O rise 1.5% to $47.99 premarket

** Co says it has expanded its multi-year partnership with Gilead GILD.O to support cancer drug research

** Collaboration gives Gilead wider access to Tempus’ real-world patient data and AI tools, which analyze medical records from cancer patients - TEM

** Gilead will use the platform to design clinical trials, choose drug targets and study treatment outcomes, co says

** Says partnership aims to speed up development of cancer medicines by combining Tempus’ data insights with Gilead’s drugmaking expertise

** Gilead has previously utilized TEM's data for its oncology research, including trial design, health outcomes analysis and clinical evidence

** As of last close, stock down ~20% YTD